Skip to main content
. 2014 Oct 1;8(6):2616–2620. doi: 10.3892/ol.2014.2582

Table II.

Association between ADAM17 expression and clinicopathological characteristics of gliomas.

ADAM17 expression

Clinicopathological features Total, n Low expression, n High expression, n P-value
Gender
 Male 36 17 19 0.653
 Female 24 11 13
Age
 <45 28 13 15 0.589
 >45 32 15 17
Tumor size, cm
 <4 24 9 15 0.185
 >4 36 19 17
Tumor location 0.789
 Frontal 18 8 10
 Temporal 23 12 11
 Other 19 8 11
Necrosis
 Absence 31 12 19 0.154
 Presence 29 16 13
KPS
 <80 33 14 19 0.320
 >80 27 14 13
WHO grade
 I–II 25 18 7 <0.005
 III–IV 35 10 25

ADAM17-positive expression rate was significantly correlated with the WHO classification of glioma grade. KPS, Karnofsky score; WHO, World Health Organization; ADAM17, a disintegrin and metalloproteinase-17; NS, not significant.